Tumor cell metabolism: cancer's Achilles' heel.

The essential hallmarks of cancer are intertwined with an altered cancer cell-intrinsic metabolism, either as a consequence or as a cause. As an example, the resistance of cancer mitochondria against apoptosis-associated permeabilization and the altered contribution of these organelles to metabolism are closely related. Similarly, the constitutive activation of signaling cascades that stimulate cell growth has a profound impact on anabolic metabolism. Here, we review the peculiarities of tumor cell metabolism that might be taken advantage of for cancer treatment. Specifically, we discuss the alterations in signal transduction pathways and/or enzymatic machineries that account for metabolic reprogramming of transformed cells.

[1]  G. Semenza,et al.  Hypoxia-Inducible Factor 1 (HIF-1) Pathway , 2007, Science's STKE.

[2]  G. Kayser,et al.  Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. , 2007, Oncology reports.

[3]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[4]  Z. Bhujwalla,et al.  Choline kinase alpha in cancer prognosis and treatment. , 2007, The Lancet. Oncology.

[5]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[6]  Richard D. Vaughan-Jones,et al.  Regulation of tumor pH and the role of carbonic anhydrase 9 , 2007, Cancer and Metastasis Reviews.

[7]  A. Morris,et al.  Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin , 2006, Diabetologia.

[8]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[9]  P. Leder,et al.  Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.

[10]  S. Henderson,et al.  Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production , 2007, Proceedings of the National Academy of Sciences.

[11]  J. Pouysségur,et al.  The Expanding Family of Eucaryotic Na+/H+Exchangers* , 2000, The Journal of Biological Chemistry.

[12]  Chi V. Dang,et al.  The interplay between MYC and HIF in cancer , 2008, Nature Reviews Cancer.

[13]  L. Galluzzi,et al.  Mitochondria as therapeutic targets for cancer chemotherapy , 2006, Oncogene.

[14]  Adrian L Harris,et al.  Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. , 2006, Cancer research.

[15]  J. Pouysségur,et al.  Hypoxia signalling controls metabolic demand. , 2007, Current opinion in cell biology.

[16]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[17]  H. Nawashiro,et al.  L‐type amino acid transporter 1 as a potential molecular target in human astrocytic tumors , 2006, International journal of cancer.

[18]  D. Spitz,et al.  2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. , 2007, Cancer research.

[19]  S. Edlbacher,et al.  Über den Stoffwechsel der Tumoren. IV. Mitteilung. , 2022 .

[20]  J. Testa,et al.  Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells , 2005, Oncogene.

[21]  Oksana Gavrilova,et al.  p53 Regulates Mitochondrial Respiration , 2006, Science.

[22]  C. Culmsee,et al.  p53 in neuronal apoptosis. , 2005, Biochemical and biophysical research communications.

[23]  A. Ullrich,et al.  Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. , 2007, Cancer research.

[24]  R. Jaenisch,et al.  HIF-1alpha is essential for myeloid cell-mediated inflammation. , 2003, Cell.

[25]  C. Boschek,et al.  Pyruvate kinase type M2 and its role in tumor growth and spreading. , 2005, Seminars in cancer biology.

[26]  Mark Muzi,et al.  Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond , 2007, Clinical Cancer Research.

[27]  S. Miyamoto,et al.  Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II , 2008, Cell Death and Differentiation.

[28]  A. Lardner.  The effects of extracellular pH on immune function , 2001, Journal of leukocyte biology.

[29]  Kou-Juey Wu,et al.  Direct regulation of TWIST by HIF-1α promotes metastasis , 2008, Nature Cell Biology.

[30]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[31]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[32]  N. Hay,et al.  Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt , 2006, Oncogene.

[33]  Eyal Gottlieb,et al.  TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.

[34]  Sébastien Bonnet,et al.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.

[35]  G. Semenza,et al.  HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. , 2007, Cancer cell.

[36]  P. Pedersen,et al.  Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen , 2007, Journal of bioenergetics and biomembranes.

[37]  D. Brizel,et al.  Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Hayashi,et al.  ROS-Generating Mitochondrial DNA Mutations Can Regulate Tumor Cell Metastasis , 2008, Science.

[39]  Lorenzo Galluzzi,et al.  Mitochondrial membrane permeabilization in cell death. , 2007, Physiological reviews.

[40]  N. Denko,et al.  HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.

[41]  J. Pouysségur,et al.  Oxygen, Hypoxia, and Stress , 2007, Annals of the New York Academy of Sciences.

[42]  R. Raval,et al.  Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. , 2006, Cancer research.

[43]  E. Gottlieb,et al.  Cell-Permeating α-Ketoglutarate Derivatives Alleviate Pseudohypoxia in Succinate Dehydrogenase-Deficient Cells , 2007, Molecular and Cellular Biology.

[44]  M. Zoratti,et al.  The mitochondrial permeability transition. , 1995, Biochimica et biophysica acta.

[45]  R. Shaw,et al.  Glucose metabolism and cancer. , 2006, Current opinion in cell biology.

[46]  G. Cheon,et al.  Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma , 2007, Molecular Cancer Therapeutics.

[47]  G. Kroemer,et al.  Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.

[48]  D. Munn,et al.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.

[49]  Martin G Pomper,et al.  Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. , 2004, Biochemical and biophysical research communications.

[50]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[51]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[52]  F. López-Ríos,et al.  Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. , 2007, Cancer research.

[53]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[54]  A. Monks,et al.  Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. , 2005, Cancer research.

[55]  Marty C. Brandon,et al.  Mitochondrial mutations in cancer , 2006, Oncogene.

[56]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[57]  Gregor Rothe,et al.  Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.

[58]  David Beach,et al.  Glycolytic enzymes can modulate cellular life span. , 2005, Cancer research.

[59]  J. Griffiths,et al.  Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. , 2006, Cancer research.

[60]  A. Maitra,et al.  Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck , 2007, Proceedings of the National Academy of Sciences.

[61]  Tao Wang,et al.  Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. , 2007, The Journal of clinical investigation.

[62]  G. Semenza,et al.  Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1 , 2007, Molecular and Cellular Biology.

[63]  Daniel E Bauer,et al.  ATP citrate lyase inhibition can suppress tumor cell growth. , 2005, Cancer cell.

[64]  G. Semenza,et al.  HIF-1 Regulates Cytochrome Oxidase Subunits to Optimize Efficiency of Respiration in Hypoxic Cells , 2007, Cell.

[65]  Jonathan Pevsner,et al.  HIF-dependent antitumorigenic effect of antioxidants in vivo. , 2007, Cancer cell.

[66]  J. Swinnen,et al.  Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. , 2007, Cancer research.

[67]  H. Christofk,et al.  Pyruvate kinase M2 is a phosphotyrosine-binding protein , 2008, Nature.

[68]  U. Grohmann,et al.  IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation , 2007, Nature Reviews Immunology.

[69]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[70]  R. Jaenisch,et al.  HIF-1α Is Essential for Myeloid Cell-Mediated Inflammation , 2003, Cell.

[71]  R. Deberardinis,et al.  Phosphatidylinositol 3-Kinase-dependent Modulation of Carnitine Palmitoyltransferase 1A Expression Regulates Lipid Metabolism during Hematopoietic Cell Growth* , 2006, Journal of Biological Chemistry.

[72]  S. Pastoreková,et al.  Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters. , 2007, American journal of physiology. Cell physiology.

[73]  Eyal Gottlieb,et al.  Mitochondrial tumour suppressors: a genetic and biochemical update , 2005, Nature Reviews Cancer.

[74]  H. Yee,et al.  A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. , 2007, Molecular cell.

[75]  C. Supuran,et al.  Targeting tumor-associated carbonic anhydrase IX in cancer therapy. , 2006, Trends in pharmacological sciences.

[76]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[77]  K. Tachibana,et al.  Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak. , 2006, Journal of the National Cancer Institute.

[78]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[79]  Yong-Ho Ahn,et al.  Up-regulation of Acetyl-CoA Carboxylase α and Fatty Acid Synthase by Human Epidermal Growth Factor Receptor 2 at the Translational Level in Breast Cancer Cells* , 2007, Journal of Biological Chemistry.

[80]  A. Ortega,et al.  Glucose avidity of carcinomas. , 2009, Cancer letters.

[81]  J. Hoek,et al.  Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. , 2005, Cancer research.

[82]  M. Dewhirst,et al.  Angiostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase. , 2007, Cancer research.